Biotech News
Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026
Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancer FREMONT, Calif. --(BUSINESS WIRE)--Oct. 21, 2026-- Personalis, Inc.
